Dr. Hyo Sook Han, MD

Dr. Han practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Han's NPI, 1306055348, was assigned on May 22, 2007. Dr. Han graduated from Seoul National University College of Medicine in 1999. Dr. Han holds Florida license ME101448.

Dr. Han's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Han also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Han's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Han to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Han practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Han's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Han is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Han's licenses on file in 3 states: Florida, California and Ohio.

Dmand AI lists breast cancer and multiple myeloma among the conditions Dr. Han treats.

CMS data shows 204 Medicare services from Dr. Han across 4 procedure codes in 2024, for 85 Medicare patients. Medicare paid $16,815 for them.

CMS counts 85 Medicare patients who saw Dr. Han in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have cancer, and 65% have high cholesterol. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Han's median patient age at 60, with 99% women.

In 2024, Dr. Han wrote 357 Medicare Part D claims for 96 patients. 68% of them were for generic drugs. CMS names the drug for 254 of them, across 8 drugs with 11 or more claims each, at $1,394,347 in total drug cost. In 2023, CMS named 251 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Han for performance year 2024, reported as part of a group. Dr. Han accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Han as offering telehealth.

Dmand AI links 86 papers to Dr. Han, published from 2011 to 2025. 2021 was the busiest year, with 15. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Receptor, ErbB-2. Dr. Han has published most often in Breast Cancer Res Treat. Dr. Han's most frequent co-authors are Hatem H. Soliman, MD, Brian J. Czerniecki, MD and Kamran Ali Ahmed, MD.

Dmand AI links Dr. Han to 15 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Neoplasm Metastasis and Brain Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 9. Open Payments lists research payments to Dr. Han that name 1 trial.

CMS Open Payments shows 101 general payments to Dr. Han from 11 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Eli Lilly and Company paid the most, $39,236. It also lists 4 research payments totaling $1,481 from 2018 to 2020, naming 1 clinical trial.

Dr. Han graduated from Seoul National University College of Medicine in 1999.

Dr. Han is in network with 8 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.